Skip to Main Content
Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite, if that is the correct word, was somehow relaxing, despite recent events. Now what passes for the usual routine has predictably returned. To cope, yes, we are firing up the trusty coffee kettle and brewing cups of stimulation. The neurons need all the help they can get. Meanwhile, here are a few items of interest as you dig in for a busy day. Keep safe and keep in touch. …

Anthony Fauci, the director of the National Institute for Allergy and Infectious Diseases, was not enthused about a decision by Moderna (MRNA) to issue snippets of early data from the Covid-19 vaccine trial his agency has been conducting without waiting for fuller results, STAT reports. That said, Fauci sees reason for cautious optimism about the Moderna vaccine, and others. The idea of having a vaccine by the end of the year is “aspirational, but it’s certainly doable,” he says.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.